CPT® Code 38225

1. Indications

The indications for performing chimeric antigen receptor T-cell (CAR-T) therapy harvesting include the following:

• Cancer Treatment This procedure is indicated for patients with certain types of cancers, particularly hematologic malignancies such as acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma, where traditional therapies have failed or are not suitable.

2. Procedure

The procedure for harvesting blood-derived T lymphocytes for CAR-T therapy involves several critical steps, which are detailed as follows:

• Step 1: Blood Collection Blood is withdrawn from the patient, typically through a process known as apheresis. This process may take place over one or more days, depending on the volume of T-lymphocytes required for the subsequent genetic modification. The blood is collected using a sterile technique to ensure patient safety and minimize the risk of infection.
• Step 2: T-Lymphocyte Separation Once the blood is collected, it undergoes a separation process where the T-lymphocytes are isolated from other blood components. This is usually achieved through centrifugation, which separates the cellular components based on their density, allowing for the collection of the desired T-cells.
• Step 3: Genetic Modification The isolated T-lymphocytes are then transported to a laboratory or manufacturing facility where they are genetically modified. This involves introducing an inactive virus that carries the genetic material necessary for the T-cells to produce chimeric antigen receptors (CARs) on their surface. This step is crucial as it enables the T-cells to recognize and attack cancer cells effectively.
• Step 4: Expansion of CAR-T Cells After the genetic modification, the T-cells are cultured and expanded in the laboratory. This process multiplies the number of CAR-T cells to hundreds of millions, ensuring that there are sufficient cells for effective treatment upon reinfusion into the patient.
• Step 5: Patient Preparation While the CAR-T cells are being manufactured, the patient receives lymphocytic cell-depleting chemotherapy. This treatment is designed to reduce the number of existing lymphocytes in the patient’s body, creating a more favorable environment for the newly infused CAR-T cells to thrive and function effectively.
• Step 6: Infusion of CAR-T Cells Once the CAR-T cells are ready and the patient has completed the preparatory chemotherapy, the modified T-cells are infused back into the patient. This step marks the culmination of the CAR-T therapy process, as the engineered T-cells are now equipped to seek out and destroy cancer cells within the patient’s body.

3. Post-Procedure

After the CAR-T cell infusion, patients are monitored closely for any potential side effects or complications. Common post-procedure care includes managing symptoms related to the infusion, such as fever, chills, or fatigue. Patients may also require supportive care to address any adverse reactions. It is essential to monitor the patient’s response to the therapy and to ensure that the CAR-T cells remain active in the body to prevent cancer recurrence. Follow-up appointments are critical to assess the effectiveness of the treatment and to manage any long-term effects that may arise from the therapy.